
When to Consider the Pancreas

Gastrointestinal upset? Nutritional deficiencies? It could be EPI.



Exocrine Pancreatic Insufficiency (EPI) Causes Decreased Production, Delivery, or Activity of Pancreatic Enzymes Needed for Proper Digestion



EPI Signs and Symptoms^{1,2}

- Flatulence
- Bloating
- Abdominal discomfort
- Fatty food intolerance

EPI Can Have Nutritional Consequences and Impact Quality of Life^{1,2}

Micronutrient and fat-soluble vitamin deficiencies

Diarrhea

Steatorrhea

Malodorous stool

- Malnutrition
- Weight loss

Observed in Patients With Chronic Pancreatitis^{3,4}

- · Impaired quality of life
- Increased mortality

EPI Is Largely a Clinical Diagnosis

Considerations in the diagnosis of EPI

Presence of EPI-Predisposing Condition ⁵⁻⁹	 Acute pancreatitis Celiac disease Chronic pancreatitis Cystic fibrosis 	 Inflammatory bowel disease Pancreatic/gastric surgery Pancreatic cancer Type 1 diabetes 	• Type 2 diabetes
Signs and Symptoms ^{5,6}	 Abdominal discomfort Bloating Diarrhea Flatulence 	 Fat soluble vitamin deficiencies Fatty food intolerance Malnutrition 	 Malodorous stool Micronutrient deficiencies Steatorrhea Weight loss
Supplemental Tests ^{5,6}	 Biochemical markers of nutritional status Direct pancreatic function test Fecal elastase-1 test Fecal fat tests 		
Patient Factors That May Delay Diagnosis ^{10,11}	 Accustomed to symptoms Embarrassment Restricting fat intake to avoid symptoms 		


When to Consider the Pancreas

Gastrointestinal upset? Nutritional deficiencies? It could be EPI.




PERT Is the Cornerstone of EPI Treatment

Pancreatic enzyme replacement therapy (PERT) is a combination of porcine-derived lipases, proteases, and amylases to aid digestion.^{5,12}



General Safety



References:

 Domínguez-Muñoz JE. Curr Gastroenterol Rep. 2007;9(2):116-122.
 Lindkvist B. World J Gastroenterol. 2013;19(42):7258-7266.
 Oleson SS et al. Pancreatology. 2014;14(6): 497-502.
 de la Iglesia-Garcia D et al. J Clin Gastroenterol. 2018;52(8):e63-e72.
 Othman MO et al. Int J Clin Pract. 2018;72(2).
 Durie P et al. Curr Med Res Opin. 2018;34(1):25-33.
 Mohapatra S et al. Pancreas. 2016;45(8):1104-1110.
 Zhang J et al. Int J Endocrinol. 2022;2022:7764963.
 Sikkens ECM et al. J Clin Gastroenterol. 2014;48(5):e43-e46.
 Hart PA et al. Curr Treat Options Gastroenterol. 2015;13(3):347-353.
 Mohapatra S et al. Pancreas. 2016;45(8):1104-1110.
 Themerican Gastroenterol ogical Association website. http://www.gastro.org/press_releases/largest-analysis-examining -barriers-to-epi-diagnosis-finds-patients-with-digestive-health-issuesoverlook-their-symptoms. Accessed January 23, 2023.
 Drugs@FDA: FDA-Approved drugs. US Drug & Food Administration. Accessed January 23, 2023.
 Chugs@FDA: FDA-Approved drugs.

